---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-036770"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T12:08:20.819852+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# EyePoint Q2 revenue $9.1M, net loss $22.9M; sells YUTIQ for $82.5M; Phase 2 data due Dec 2023

## Summary
- Net product revenue fell to $5.3M from $11.3M due to YUTIQ sale and DEXYCU discontinuation.
- Sold YUTIQ franchise to Alimera Sciences for $82.5M cash plus future royalties; retired all bank debt.
- Phase 2 DAVIO 2 (wet AMD) topline data due Dec 2023; no drug-related SAEs reported to date.
- Phase 2 PAVIA (NPDR) fully enrolled (77 patients), topline expected Q2 2024.
- Jay S. Duker appointed President and CEO; Nancy Lurker transitioned to Executive Vice Chair of Board.

## SEC filing metadata
- accession: 0000950170-23-036770
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017023036770/0000950170-23-036770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017023036770/eypt-20230802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-036770
- JSON: https://secwatch.observer/filing/0000950170-23-036770.json
- Plain text: https://secwatch.observer/filing/0000950170-23-036770.txt

## Key facts
- Earnings Releases
  EyePoint, Inc. reported second quarter ended June 30, 2023 results: revenue total net revenue was $9.1 million.
  - Period: second quarter ended June 30, 2023
  - Revenue: total net revenue was $9.1 million
  - Result: reported results
  source text: For the second quarter ended June 30, 2023, total net revenue was $9.1 million compared to $11.6 million for the quarter ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017023036770/0000950170-23-036770-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.